31 / 210
Ponencias
31
11. Eckhardt CL, van Velzen AS, Peters M, Astermark J, Brons PP, Cas-
taman G, et INSIGHT Study Group. Factor VIII gene (F8) mutation
and risk of inhibitor development in nonsevere hemophilia A. Blood
2013;12;122(11):1954-62. DOI: 10.1182/blood-2013-02-483263.
Epub 2013Aug 7. Erratum in: Blood 2014;8;123(19):3056. PubMed
PMID: 23926300.
12. Goodeve AC, Pavlova A, Oldenburg J. Genomics of bleeding disor-
ders. Haemophilia 2014;20(Suppl 4):50-3. DOI: 10.1111/hae.12424.
Review. PubMed PMID: 24762275; PubMed Central PMCID:
PMC4274361.
13. Leissinger CA. Advances in the clinical management of inhibitors
in hemophilia A and B. Semin Hematol 2016;53(1):20-7. DOI:
10.1053/j.seminhematol.2015.10.008. Epub 2015 Oct 27. Review.
PubMed PMID: 26805903.
14. Peyvandi F, Mannucci PM, Garagiola I, El-Beshlawy A, Elalfy M,
RamananV, et al.A Randomized Trial of FactorVIII and Neutralizing
Antibodies in Hemophilia A. N Engl J Med 2016;26;374(21):2054-
64. DOI: 10.1056/NEJMoa1516437. PubMed PMID: 27223147.
15. Michaelides K, Tuddenham EG, Turner C, Lavender B, Lavery
SA. Live birth following the first mutation specific pre-implan-
tation genetic diagnosis for haemophilia A. Thromb Haemost
2006;95(2):373-9. PubMed PMID: 16493501.
16. Biere-Rafi S, Baarslag MA, Peters M, Kruip MJ, Kraaijenhagen RA,
Den Heijer M, et al. Cardiovascular risk assessment in haemophilia
patients. Thromb Haemost 2011;105(2):274-8. DOI: 10.1160/TH10-
07-0460. Epub 2010 Dec 6. PubMed PMID: 21136012.
17. Ferraris VA, Boral LI, CohenAJ, Smyth SS, White GC 2nd. Consen-
sus review of the treatment of cardiovascular disease in people with
hemophilia A and B. Cardiol Rev 2015;23(2):53-68. DOI: 10.1097/
CRD.0000000000000045. Review. PubMed PMID: 25436468; Pub-
Med Central PMCID: PMC4323575.
18. Altisent C, Martorell M, de la Sierra A. Sodium content in products
used to treat haemophilia. Haemophilia 2016;26. DOI: 10.1111/
hae.12948. [Epub ahead of print] PubMed PMID: 27228069.
19. Nathwani AC, Reiss UM, Tuddenham EG, Rosales C, Chowdary P,
McIntosh J, et al. Long-term safety and efficacy of factor IX gene
therapy in hemophilia B. N Engl J Med 2014;20;371(21):1994-2004.
DOI: 10.1056/NEJMoa1407309. PubMed PMID: 25409372; Pub-
Med Central PMCID: PMC4278802.
20. Arruda VR, Samelson-Jones BJ. Obstacles and future of gene thera-
py for hemophilia. Expert Opin Orphan Drugs.2015;3(9):997-1010.
Epub 2015 Jul 18. PubMed PMID: 26900534; PubMed Central
PMCID: PMC4756761.
21. Fomin ME, Togarrati PP, Muench MO. Progress and challenges in
the development of a cell-based therapy for hemophilia A. J Thromb
Haemost 2014;12(12):1954-65. DOI: 10.1111/jth.12750. Epub
2014 Oct 31. Review. PubMed PMID: 25297648; PubMed Central
PMCID: PMC4388483.
22. Mannucci PM, Mancuso ME, Santagostino E, Franchini M. Inno-
vative Pharmacological Therapies for the Hemophilias Not Based
on Deficient Factor Replacement. Semin Thromb Hemost 2016;5.
[Epub ahead of print] PubMed PMID: 27148843.